At a glance
- Originator Novartis
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol ester transfer protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 12 Oct 1998 New profile
- 06 Oct 1998 Preclinical development for Hyperlipidaemia in USA (Unknown route)